Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
0.6482
-0.0545 (-7.76%)
At close: Oct 23, 2026, 4:00 PM EDT
0.6600
+0.0118 (1.82%)
After-hours: Oct 23, 2026, 6:44 PM EDT
Milestone Pharmaceuticals Employees
Milestone Pharmaceuticals had 38 employees as of December 31, 2025. The number of employees increased by 5 or 15.15% compared to the previous year. That makes Milestone Pharmaceuticals the 36,282nd largest employer in the world and 4,965th in the United States.
Employees
38
Change (1Y)
5
Growth (1Y)
15.15%
Revenue / Employee
$61,658
Profits / Employee
-$2,210,816
Market Cap
91.34M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 38 | 5 | 15.15% |
| Dec 31, 2024 | 33 | -14 | -29.79% |
| Dec 31, 2023 | 47 | 8 | 20.51% |
| Dec 31, 2022 | 39 | 10 | 34.48% |
| Dec 31, 2021 | 29 | 1 | 3.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| LENZ Therapeutics | 152 |
| Immunic | 100 |
| ImmuCell | 73 |
| Aardvark Therapeutics | 28 |
| NeurAxis | 24 |
| Tevogen | 18 |
| Atara Biotherapeutics | 10 |
| Coya Therapeutics | 8 |
MIST News
- 3 days ago - Milestone Pharmaceuticals price target lowered to $5 from $6 at Raymond James - TheFly
- 4 days ago - Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences - GlobeNewsWire
- 14 days ago - Milestone Pharmaceuticals enrolls first European patient in ReVeRA-301 trial - TheFly
- 14 days ago - Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial - GlobeNewsWire
- 15 days ago - Milestone Pharmaceuticals management to meet virtually with Cantor - TheFly
- 4 weeks ago - Milestone announces Montreal Heart Institute enrolled first patient - TheFly
- 4 weeks ago - Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR - GlobeNewsWire
- 5 weeks ago - Milestone Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts